NCT05564390 2026-03-18
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
11 trialsNCT05732961 2025-12-10
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT04064060 2025-11-12
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Celgene
Phase 3 Recruiting
NCT04717414 2025-07-10
INDEPENDENCE
Celgene
Phase 3 Active not recruiting
NCT01688011 2025-07-03
Connect® Myeloid Disease Registry
Celgene
Terminated
NCT06927232 2025-04-15
AZA+Lus VS AZA Monotherapy in HR-MDS
Peking Union Medical College Hospital
Phase 3 Not yet recruiting
NCT05005182 2024-09-19
Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts
Mayo Clinic
Phase 2 Terminated
NCT06254781 2024-02-12
Luspatercept in Metastatic AGCT of the Ovary
University Health Network, Toronto
Phase NA Completed
NCT03194542 2023-08-24
A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence
Celgene
Phase 2 Completed
NCT02604433 2023-04-18
BELIEVE
Celgene
Phase 3 Completed
NCT02631070 2021-12-17
MEDALIST
Celgene
Phase 3 Completed